249 related articles for article (PubMed ID: 28426105)
1. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
Pruneri G; Lazzeroni M; Bagnardi V; Tiburzio GB; Rotmensz N; DeCensi A; Guerrieri-Gonzaga A; Vingiani A; Curigliano G; Zurrida S; Bassi F; Salgado R; Van den Eynden G; Loi S; Denkert C; Bonanni B; Viale G
Ann Oncol; 2017 Feb; 28(2):321-328. PubMed ID: 28426105
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
Schiza A; Thurfjell V; Stenmark Tullberg A; Olofsson H; Lindberg A; Holmberg E; Bremer T; Micke P; Karlsson P; Wärnberg F; Strell C
Eur J Cancer; 2022 Jun; 168():128-137. PubMed ID: 35236568
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.
Komforti M; Badve SS; Harmon B; Lo Y; Fineberg S
Histopathology; 2020 Nov; 77(5):749-759. PubMed ID: 32557780
[TBL] [Abstract][Full Text] [Related]
6. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
7. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
[TBL] [Abstract][Full Text] [Related]
9. Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
Khoury T; Quinn M; Tian W; Yan L; Zhan H
Histopathology; 2022 Jan; 80(2):291-303. PubMed ID: 34379814
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
11. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.
Wu SL; Yu X; Mao X; Jin F
BMC Cancer; 2022 Jul; 22(1):782. PubMed ID: 35843951
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
14. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
[TBL] [Abstract][Full Text] [Related]
15. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
18. Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
Guerini-Rocco E; Bellerba F; Concardi A; Taormina SV; Cammarata G; Fumagalli C; Guerrieri-Gonzaga A; Macis D; Del Fiol Manna E; Balladore E; Cannone M; Veronesi P; Fusco N; Bonanni B; Viale G; Barberis M; Gandini S; Lazzeroni M
Eur J Cancer; 2024 May; 203():114063. PubMed ID: 38615592
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma
Farolfi A; Petracci E; Serra L; Ravaioli A; Bravaccini S; Ravaioli S; Tumedei MM; Ulivi P; Canale M; Puccetti M; Falcini F; Folli S; Curcio A; Rocca A
Front Oncol; 2020; 10():1486. PubMed ID: 32974178
[TBL] [Abstract][Full Text] [Related]
20. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
